Left Ventricular Sphericity Index is a reproducible bedside echocardiographic measure of geometric change between acute phase Takotsubo’s syndrome and acute anterior myocardial infarction

Shaun Khanna a,⇑, Aditya Bhat a, Henry H. Chen a, Jeremy W.A. Tan a, Gary C.H. Gan a, Timothy C. Tan a,b,c

a Department of Cardiology, Blacktown Hospital, Blacktown Road, Blacktown, NSW 2148, Australia
b University of New South Wales, Faculty of Medicine, Sydney, NSW 2052, Australia
c Western Sydney University, Faculty of Medicine, Blacktown 2148, NSW, Australia

ABSTRACT

Background: Left ventricular sphericity index (LVSI) is a simple, quick and reproducible measure to evaluate LV geometric changes. The aim of our study was to evaluate the utility of LVSI as a rapid discrimination tool in two disease processes; Takotsubo’s Syndrome (TS) and Anterior Myocardial Infarction (AMI), in the absence of significant left ventricular systolic dysfunction.

Methods: Consecutive patients with acute phase TS admitted to our institution (Jan 2013 - Dec 2018) were evaluated (n=66). Patients with a comprehensive two-dimensional transthoracic echocardiogram were included in primary analysis (n=50) and age-matched with a cohort of patients with acute anterior AMI (n=50). Appraisal of demographic, clinical and echocardiographic parameters of patients was undertaken. Biplane LVSI was calculated as an average of the short- and long-axis length in the 4- and 2-chamber apical views.

Results: A total of 50 TS patients (64.3±13.7 years, 18% men) were matched with 50 AMI (62.1±12.84 years, 74% men) patients. There was no significant difference in baseline cardiovascular risk factors other than diabetes mellitus (AMI 34% vs TS 17%, p = 0.034). There was also no difference in LV mass (p=0.10) or LVEF (p=0.52) between the two groups. Interestingly, there was a significant difference in mean LVSI between TS (0.60±0.06) vs AMI (0.52±0.07) (p<0.01) reflecting a more spherical shaped left ventricle in the acute TS group.

Conclusions: LVSI is reflective of geometric changes in the left ventricle and may be helpful as a rapid and reproducible diagnostic tool in differentiating between TS and AMI in the acute phase.

1. Introduction

Takotsubo’s syndrome (TS) has historically been defined as a transient myocardial disease process resulting in a classical apical hypokinesis with a reversible regional dilatation of the left ventricle [1]. The pathogenesis of this entity is attributed to a catecholamine surge, usually secondary to a physical and/or emotional stressor [1,2]. The presentation of acute TS can be similar to that of an acute anterior myocardial infarction (AMI) [2]. Despite well-established pathognomonic morphological features defining TS, distinguishing between the two conditions may not be straightforward [3]. Both these conditions have very different pathophysiological processes, though distinguishing between the two conditions in the acute phase can be challenging especially in more subtle cases where left ventricular systolic dysfunction is not significantly impaired. We hypothesise that different LV geometric shape changes may be associated with the different pathophysiological processes hence could potentially be used to help differentiate between both conditions with similar clinical acute presentations.

Transthoracic echocardiography (TTE) is a simple and readily available bedside tool which can provide first line imaging and valuable information in patients with acute TS or AMI. However, traditional echocardiographic measures of such as LV ejection fraction (LVEF) and indexed LV mass (LVMI), can frequently be insufficient to differentiate between the two different pathologies in the acute phase [4]. LVSI is an underutilised measurement of LV geometry, a marker of LV remodelling, that can be easily obtained from standard echocardiographic images [5,6]. LVSI has been validated...
as a direct measure of LV remodelling in patients with idiopathic dilated cardiomyopathy (IDCM) and correlated with outcomes in ACS populations [6–10]. However, the utility and value of this imaging parameter in differentiating between acute phase TS and AMI has never been studied. Hence the aim of our study was to characterise the geometric changes between acute TS and AMIs using LVSI.

2. Methods

2.1. Study population

Patients with a clinical diagnosis of acute phase TS infarction between January 2013 to December 2018 that presented to our institution were retrospectively examined. Patients who were >18 years of age presenting with clinical syndrome that is consistent with TS and who underwent coronary angiography and a comprehensive TTE within 72 h of admission which demonstrated normal LVEF were included. These patients were age-matched in a 1 to 1 ratio with patients presenting with an acute ST elevation myocardial infarct (STEMI) within the same period. Patients with ventricular or supra-ventricular arrhythmias, congenital heart disease, significant valvular heart disease or prosthetic valves, missing baseline clinical data or had poor quality echo images were excluded. The study protocol was approved by the Human Research and Ethics Committee of New South Wales (1910-06 QA).

2.2. Transthoracic echocardiography

Standard transthoracic echocardiography was performed using commercially available ultrasound equipment (EPIQ, Philips Medical Systems, Andover, MA; GE E9, GE Healthcare, Milwaukee, WI; GE 95, GE Healthcare, Milwaukee, WI) according to guideline recommendations by the American Society of Echocardiography. All echocardiographic images were saved in digital format and analysis was performed offline by two investigators who were blinded to the clinical data of the patient.

Left ventricular sphericity index (LVSI) was measured offline by two independent researchers, blinded to the patient history and condition. LVSI was calculated as LV basal radial length/longitudinal length, measured in both the apical 4- and 2-chamber views during end-diastole (ED) and end-systole (ES) (see Fig. 1). An average of four measurements of LVSI from 3 cardiac cycles (i.e. ES/ED in apical 4-chamber and ES / ED in apical 2-chamber) was reported.

2.3. Intra- and inter-observer variability

Intra- and inter-observer variability was assessed by repeating LVSI in 20 randomly selected patients from the cohort >4 weeks apart by the same investigator and by a second independent investigator. There was good inter- and intra-observer agreement for the LVSI measurements, with an interclass correlation of 0.96 with a 95% Confidence Interval of 0.90–0.99 and a coefficient of variation of 3.39 with a 95% Confidence Interval of 1.65–5.14.

2.4. Statistical analysis

All statistical analyses were performed using commercially available software (SPSS version 22; SPSS Inc, Chicago, IL, USA). Variable distribution was reported as mean and standard deviation for normally distributed variables, median and interquartile range for non-normally distributed variables or as percentage for categorical variables. Comparison between mean values between TS and AMI groups was performed with Student T test for unpaired data or ANOVA with analysis of variance and Bonferroni correction. Categorical variables were compared with Chi - square test (with Yates correction) or with Fisher test. All tests were 2-tailed. A p value of <0.05 was considered as statistically significant.

3. Results

3.1. Baseline characteristics

The final cohort consisted of 100 patients, which included 50 patients with diagnosed acute TS (64.3 ± 13.7 years, 18% men) and 50 patients with anterior STEMI (62.10 ± 12.84 years, 74% men). Patients in the AMI population had higher rates of diabetes mellitus (p = 0.03) but no other significant differences in the baseline characteristics between groups. See Table 1.

| Table 1 Baseline characteristics. |
|----------------------------------|
| **Baseline characteristics** | **TS (n = 50)** | **AMI (n = 50)** | **p value** |
| Age (years) | 64.30 ± 13.80 | 62.10 ± 12.80 | 0.41 |
| Men | 9 (18%) | 37 (74%) | <0.01 |
| Body mass index (kg/m²) | 26.9 ± 8.3 | 29.1 ± 6.4 | 0.19 |
| Peak Troponin Level | 5145 ± 5925 | 27519 ± 33619 | <0.01 |
| Hypertension | 11 (22%) | 18 (36%) | 0.185 |
| Diabetes Mellitus | 25 (50%) | 23 (46%) | 0.689 |
| Obesity | 7 (14%) | 17 (34%) | 0.034 |
| Hypertension | 11 (22%) | 15 (30%) | 0.34 |
3.2. Echocardiographic parameters

Baseline TTE data was compared between the two groups. No significant differences were seen between the two groups in terms of LV size and function (TS LVEF 54 ± 12% vs AMI LVEF 53 ± 14%, p = 0.69). There were no significant differences in diastolic parameters (mitral E', A', E/A ratio or deceleration time) between the two groups. However, there was a significant difference in calculated LVSI between the two groups (TS 0.6 ± 0.6 vs AMI 0.5 ± 0.7, p < 0.01) which suggested that patients with acute TS had more spherical shaped left ventricles in the compared to acute anterior MI patients. See Table 2.

4. Discussion

This study attempted to characterise left ventricular geometric changes using a quantitative measure of LV shape i.e. LVSI between acute phase TS and AMI, two fundamentally different cardiac pathologies but with similar clinical presentations. Our results indicate that in acute phase TS process, the LV adopts a more spherical morphology compared to patients with anterior STEMI [11]. Due to large similarities in clinical history, examination, electrocardiography and traditional echocardiographic findings of regional wall motion abnormalities differentiation between the two conditions can be difficult particularly if left ventricular systolic function is within normal limits [12,13]. The present gold-standard investigation which differentiates between these two pathologies is coronary angiography. More recently, echo measures of LVSI between the two groups (TS 0.6 ± 0.6 vs AMI 0.5 ± 0.7, p < 0.01) which suggested that patients with acute TS had more spherical shaped left ventricles in the compared to acute anterior MI patients. See Table 2.

5. Conclusions

The LVSI parameter provides a simple but more objective quantification of LV geometric changes, and hence could potentially be used as an additional quantitative tool in discriminating these two pathologies in addition to standard diagnostic criteria. Further studies are still required to better characterise the application of this measure in a clinical setting.

Sources of support

Not applicable.

CRediT authorship contribution statement

Shaun Khanna: Methodology, Investigation, Resources, Writing - original draft. Aditya Bhat: Writing - review & editing, Formal analysis, Project administration. Henry H. Chen: Writing - review & editing, Formal analysis. Jeremy W.A. Tan: Investigation, Resources, Validation. Gary C.H. Gan: Formal analysis, Data curation, Supervision. Timothy C. Tan: Supervision, Project administration, Conceptualization, Writing - review & editing.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] K. Komamura, M. Fukui, T. Iwasaku, S. Hirotani, T. Masuyama, Takotsubo cardiomyopathy: Pathophysiology, diagnosis and treatment, World. J. Cardiol. 6 (2014) 602–609.
[2] M. Izumo, Y.J. Akashi, Role of echocardiography for takotsubo cardiomyopathy: clinical and prognostic implications, Cardiovasc. Diagn. Ther. 8 (2018) 98–108.
[3] D.C. Scantlebury, A. Prasad, Diagnosis of Takotsubo cardiomyopathy, Circ. J. 78 (2014) 2120–2139.
[4] A.B. Halima, A. Zidi. The cardiac magnetic resonance sphericity index in the acute phase of takotsubo cardiomyopathy: Pathophysiology, diagnosis and treatment, World. J. Cardiol. 6 (2014) 602–609.
[5] D.C. Scantlebury, A. Prasad, Diagnosis of Takotsubo cardiomyopathy, Circ. J. 78 (2014) 2120–2139.
[6] M.A. Konstam, D.G. Kramer, A.R. Patel, M.S. Maron, J.E. Udelson, Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment, JACC Cardiovasc. Imaging. 4 (2011) 98–108.
[7] A. Sadeghpour, F. Abtahi, M. Kavar, M. Esmaeilzadeh, N. Samiei, S.Z. Ojaghi, H. Bakhshandeh, M. Maleki, F. Noohi, A. Mohhebbi, Echocardiographic evaluation of mitral geometry in functional mitral regurgitation, J. Cardiothorac. Surg. 54 (2008) 54.
[8] A.B. Halima, A. Zidi. The cardiac magnetic resonance sphericity index in the acute phase of takotsubo cardiomyopathy: Pathophysiology, diagnosis and treatment, World. J. Cardiol. 6 (2014) 602–609.
D. Stolfo, M. Merlo, B. Pinamonti, G. Barbati, A. Di Lenarda, G. Sinagra, Evolution of left ventricular sphericity index in idiopathic dilated cardiomyopathy: clinical and prognostic implications, Eur. Heart. J. Supplements. 34 (2013) 1196.

J.J. Gomez-Doblas, J. Schor, P. Vignola, D. Weinberg, E. Traad, R. Carrillo, D. Williams, G.A. Lamas, Left ventricular geometry and operative mortality in patients undergoing mitral valve replacement, Clin. Cardiol. 24 (2001) 717–722.

S. Anvari, M.A. Akbarzadeh, F. Bayat, M.H. Namazi, M. Safi, Left ventricular sphericity index analysis for the prediction of appropriate implantable cardioverter-defibrillator therapy, Pacing. Clin. Electrophysiol. 41 (2018) 1192–1196.

S.P. Wong, J.K. French, A.M. Lydon, S.O. Manda, W. Gao, N.G. Ashton, H.D. White, Relation of left ventricular sphericity to 10-year survival after acute myocardial infarction, Am. J. Cardiol. 94 (2004) 1270–1275.

H.F. Mannaerts, J.A. van der Heide, O. Kamp, M.G. Stoel, J. Twisk, C.A. Visser, Early identification of left ventricular remodelling after myocardial infarction, assessed by transthoracic 3D echocardiography, Eur. Heart. J. 25 (2004) 680–687.

M. Inoue, M. Shimizu, H. Ino, M. Yamaguchi, H. Terai, N. Fujino, K. Sakata, A. Funada, R. Tatami, S. Ishise, H. Kanaya, H. Mabuchi, Differentiation between patients with takotsubo cardiomyopathy and those with anterior acute myocardial infarction, Circ. J. 69 (2005) 89–94.

S. Kurisu, I. Inoue, T. Kawagoe, M. Ishihara, Y. Shimatani, S. Nakamura, M. Yoshida, N. Mitsuba, T. Hata, H. Sato, Time course of electrocardiographic changes in patients with Tako-Tsubo syndrome: comparison with acute myocardial infarction with minimal enzymatic release, Circ. J. 68 (2004) 77–81.

L. Cai, K. Addetta, D. Medvedofsky, K.T. Spencer, Myocardial strain may be useful in differentiating Takotsubo cardiomyopathy from left anterior descending coronary artery ischemia, Int. J. Cardiol. 1 (2017) 359–363.

M. Ahmed, T.P. Fitzgibbons, P. Shaw, A. Iskander, J.E. Valle, J. Bote, D. Tighe, G.P. Aurigemma. Can longitudinal strain profile reliably distinguish Takotsubo cardiomyopathy from acute LAD territory MI?: analysis using speckle tracking imaging, Circulation 130 (2014) A18154.

J.R. Ghadri, I.S. Wittstein, A. Prasad, S. Sharkey, K. Dote, Y.J. Akashi, et al., International expert consensus document on Takotsubo syndrome (Part II): diagnostic workup, outcome, and management, Eur. Heart. J. 39 (2018) 2047–2062.

R. Citro, A.R. Lyon, P. Meimoun, E. Omerovic, B. Redfors, T. Buck, Standard and advanced echocardiography in takotsubo (stress) cardiomyopathy: clinical and prognostic implications, J. Am. Soc. Echocardiogr. 28 (2015) 57–74.

M. Hanna, R.S. Finkelhor, W.F. Shaw, R.C. Bahler, Extent of right and left ventricular focal wall-motion abnormalities in differentiating transient apical ballooning syndrome from apical dysfunction as a result of coronary artery disease, J. Am. Soc. Echocardiogr. 20 (2007) 144–150.